Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

September 1, 2023

Study Completion Date

August 31, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DIAGNOSTIC_TEST

Whole body 18F-FDG PET/CT

In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.

Trial Locations (3)

2100

Rigshospitalet, Copenhagen

2730

Herlev Hospital, Herlev

2900

Gentofte Hospital, Gentofte Municipality

All Listed Sponsors
collaborator

Danish Lung Cancer Group

OTHER

collaborator

Danish Comprehensive Cancer Center

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT03740126 - Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy | Biotech Hunter | Biotech Hunter